Quicklists
Javascript must be enabled

Doron Levy : Modeling the role of the immune response in chronic myelogenous leukemia (Apr 15, 2016 11:55 AM)

Tyrosine kinase inhibitors (TKIs), such as imatinib (IM), have significantly improved treatment of chronic myelogenous leukemia (CML). However, the majority of patients are not cured for undetermined reasons. It turns out that many patients who otherwise responded well to IM therapy still show variations in their BCR-ABL transcripts. In this talk we will overview mathematical models for leukemia, drug resistance, and stem cells. Our main focus will be on our recent results concerning mathematical models that integrate CML and an autologous immune response.  This is a joint work with G. Clapp, T. Lepoutre, and F. Nicolini.

Add to Favorites

Please select playlist name from following

Create new playlist

Report Video

Please select the category that most closely reflects your concern about the video, so that we can review it and determine whether it violates our Community Guidelines or isn’t appropriate for all viewers. Abusing this feature is also a violation of the Community Guidelines, so don’t do it.

0 Comments

Comments Disabled For This Video